IgAN is a key focus for Novartis, driving a decision to acquire Chinook Therapeutics for $3.2 billion upfront earlier this year, adding a pair of late clinical-stage programmes for the disease ...
In January this year Bicycle Therapeutics bolstered its drug development brainpower by recruiting Nicholas Keen to be its chief scientific officer, poaching him from his role as head of Novartis ...
After hours: February 14 at 6:48:23 PM EST Loading Chart for FOLD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback